# About Sermorelin Medicinal: An Independent Editorial Digest

> Sermorelin Medicinal is an independent editorial project that publishes cited summaries of the peer-reviewed GHRH(1-29) literature. Not a clinic, not a vendor, not a prescription service.

An independent editorial wall for the GHRH(1-29) research record — what we are, what we are not, and how we read the literature.

## What this site is

Sermorelin Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin — the GHRH(1-29) peptide. We read the published record and stencil it onto the wall: the mechanism, the studied doses, the body-composition findings, the half-life, and the hard limits of the adult data, each figure carried back to the study that measured it.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## What the name means

The word "medicinal" in this domain is editorial framing, not a service claim. It marks the position this publisher occupies relative to the literature — reading sermorelin as a subject of medical research — not a statement that the site offers treatment, consultation, compounding, or prescriptions. There is no clinic behind this wall, no dispensary, and no counter.

We do not have doctors, pharmacists, or a clinical team. When a page reports what was administered in a study, it reports a study parameter — never an instruction. The site gives no human dosing recommendations anywhere.

## How we read the record

Three rules govern the reading. First, numbers first, attribution after: every quantitative claim — a height velocity, an IGF-1 percentage, a half-life, a body-fat change — maps to a numbered citation with a DOI or PubMed link. Second, lanes stay separate: where body-composition evidence comes from the stabilized analog tesamorelin rather than from sermorelin itself, we say so, so a drug-class finding is never dressed up as a sermorelin-specific result.

Third, the limits are stencilled as loudly as the findings. The anti-aging marketing for this compound outpaces its evidence; the approval history is widely misstated; the long-term adult safety data are thin. We mark each of those in plain view rather than burying them.

## On the regulatory record

We state sermorelin's regulatory history precisely because it is so often garbled. Sermorelin was a fully FDA-approved prescription product for pediatric growth-hormone deficiency, withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy — and is now prepared by compounding pharmacies as a Category 1 bulk drug substance under FDA's Section 503A framework. It is a formerly approved, now-compounded GHRH analog: not currently a marketed finished drug, and not a compound that was "never approved." Growth-hormone secretagogues, including GHRH analogs, are also prohibited in sport under the WADA Prohibited List.

---

The GHRH(1-29) record stencilled onto raw concrete — the pulsatile-GH mechanism, the studied doses, the body-composition data filed where it belongs as tesamorelin, the formerly-approved-then-withdrawn history set straight, and the thin adult-safety line sprayed in caution-orange; no clinic behind the wall and nothing here dosed, compounded, or sold.